Sections
In 2024, the AACR reported another year of positive operating returns. This financial stability enables the AACR to comprehensively meet the challenges of the cancer problem. Operating revenues totaled $122 million and total expenditures were $92.7 million. The net impact of revenues and expenses resulted in an operating surplus of $29 million. As outlined in this report, several major projects were launched in 2024, and the AACR was able to outperform the budget through successful programming, revenue growth, and prudent financial management.
Non-operating activities are primarily related to long-term investments. The AACR’s investments provided strong returns in the amount of $21.6 million in 2024 and outperformed comparable market indexes.
As a result of the financial performance for the year 2024, the AACR’s unrestricted net assets are now $204 million. These reserves ensure continued investment in the scientific programs and initiatives that support the AACR’s mission to prevent and cure all cancers.
Unrestricted Revenues and Expenses
As of December 31, 2024
| 2024 | ||
| REVENUE | ||
| Membership Dues | $4,251,233 | |
| Scientific Meetings and Educational Workshops | $33,340,841 | |
| Publications | $19,695,235 | |
| Other Revenue | $11,028,985 | |
| Subtotal Program Revenue | $68,316,294 | |
| Support | ||
| NIH Grants | $283,527 | |
| Contributions | $54,454,400 | |
| Subtotal Support Revenue | $54,737,927 | |
| TOTAL REVENUE | $123,054,221 | |
| EXPENSES | ||
| Scientific Meetings and Educational Workshops | $24,505,530 | |
| Research Grants and Scientific Awards | $14,674,112 | |
| Scientific Publications | $13,309,826 | |
| Professional Education and Scientific Programs | $13,692,008 | |
| Communications, Science Policy & Patient Education | $10,148,040 | |
| Member Services | $3,450,327 | |
| Subtotal Program Services | $79,779,843 | |
| Support Services | $5,693,967 | |
| Fundraising and Development | $7,053,392 | |
| Subtotal Supporting Services | $12,747,359 | |
| TOTAL EXPENSES | $92,527,202 | |
| Operating Surplus before Investments | $30,527,019 | |
| Other Changes | ||
| Investment Income/(loss) | $21,705,690 | |
| Subtotal Other Changes | $21,705,690 | |
| Change in Unrestricted Net Assets | $52,232,709 | |
| NET ASSETS BEGINNING OF YEAR | $153,153,686 | |
| NET ASSETS END OF YEAR | $205,386,395 |
